DiscoverMarket PathwaysDo We Need an Expedited Medtech Reimbursement Program? An Interview with Mark McClellan
Do We Need an Expedited Medtech Reimbursement Program? An Interview with Mark McClellan

Do We Need an Expedited Medtech Reimbursement Program? An Interview with Mark McClellan

Update: 2022-05-13
Share

Description

One of the hottest issues in medtech reimbursement is whether there is a  need for an expedited reimbursement program following the repeal of  MCIT. In this episode of the Market Pathways podcast, former CMS  Administrator and FDA Commissioner Mark McLellan weighs in on this and  other reimbursement and regulatory concerns facing the device industry.  


#medtech #MedicalDevices #FDA #CMS #MCIT


View the latest issue of Market Pathways: https://bit.ly/3M4gsLc


View more podcast episodes: https://bit.ly/3vgFTlT


About Market Pathways


Your premium guide to global medical device regulation, reimbursement   and  policy. Market Pathways delivers incomparable intelligence   exploring the  people, challenges, and opportunities impacting the   global medtech  regulatory and reimbursement community. View the latest   issue of Market  Pathways on MyStrategist.com

Comments 
In Channel
loading
00:00
00:00
x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Do We Need an Expedited Medtech Reimbursement Program? An Interview with Mark McClellan

Do We Need an Expedited Medtech Reimbursement Program? An Interview with Mark McClellan

Market Pathways